Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €66.97 EUR
Change Today -0.90 / -1.32%
Volume 0.0
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures, and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation (AF) therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Products The company’s six principal product categories are tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker (pacemaker) systems, AF products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs, heart failure (HF) monitoring devices, and other vascular accessories), structural heart products (heart valve replacement and repair products, and structural heart defect devices), and neuromodulation products (spinal cord stimulation (SCS) and radiofrequency (RF) ablation (RFA) to treat chronic pain and deep brain stimulation to treat movement disorders). ICD Systems The company’s tachycardia ICD systems and cardiac resynchronization therapy defibrillator (CRT-D) devices treat patients with hearts that beat inappropriately fast - a condition known as tachycardia. An ICD monitors the heartbeat and delivers high-energy electrical impulses, or ‘shocks’, to treat potentially lethal, abnormally fast heart rhythms -- ventricular tachycardia (VT) and ventricular fibrillation (VF) -- which lead to sudden cardiac death (SCD). In VT, the lower chambers of the heart (ventricles) contract at an abnormally rapid rate and typically deliver less blood to the body's tissues and organs. VT could progress to VF, in which the heart beats so rapidly and erratically that it could no longer pump blood. A CRT-D device resynchronizes the beating of the ventricles, which beat out of sync in HF patients, and provides backup treatment for SCD, which is a risk factor associated with certain types of HF. Cardiac resynchronization therapy could improve the quality of life for various patients with HF, a progressive condition in which the heart weakens and loses its ability to pump an adequate supply of blood. The company received FDA (the U.S. Food and Drug Administration) approval and European CE Mark approval for its next generation Ellipse ICD and SJM Assura family of ICD and CRT-D devices. The SJM Assura family of high-voltage devices features both ICD models (Fortify Assura) and CRT-D models (Unify Assura for bi-polar CRT-D and Quadra Assura for quadripolar CRT-D). The Ellipse ICD is a high-energy ICD denoted for its small size, while the Assura family has a high-energy output, with a maximum output of 40 Joules. The Assura family also includes the company’s Unify Quadra CRT-D device (FDA approval and European CE Mark approval) and the company’s Quartet LV (left ventricular) lead (FDA approval and European CE Mark approval). The company’s Unify Quadra, Quadra Assura and Promote Quadra represent quadripolar pacing systems that are available worldwide. These quadripolar pacing systems allow physicians various options to address pacing complications without the need to reposition a lead surgically. In 2013, the company announced European CE Mark approval of its next-generation quadripolar device, the Quadra Assura MP CRT-D device, which features MultiPoint Pacing technology that enables physicians to pace multiple locations on the left side of the heart with a single lead, thereby providing various options to optimize CRT pacing to meet individual patient needs. The Assura family replaces the company’s Unify CRT-D and Fortify ICD devices (FDA approval and European CE Mark approval). All of the company’s high-voltage device families are available with the DF4 connector that allows a single defibrillation lead connection between an ICD or CRT-D device and the heart, reducing the procedure time and volume of leads implanted in the chest cavity. The company’s ICDs are used with the single and dual-shock electrode transvenous d

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €66.97 EUR -0.90

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.34 USD +0.09
CR Bard Inc $196.65 USD +3.55
Olympus Corp ¥4,750 JPY +5.00
Smith & Nephew PLC 1,189 GBp +22.00
Zimmer Biomet Holdings Inc $104.07 USD -0.78
View Industry Companies
 

Industry Analysis

JUD

Industry Average

Valuation JUD Industry Range
Price/Earnings 20.6x
Price/Sales 3.8x
Price/Book 5.5x
Price/Cash Flow 18.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.